Featured in: Poor Research
Lyme retreatment guidance may be flawed
Deer ticks, Lyme disease, and medical guidance Accepted medical practice discourages antibiotic retreatment in cases where Lyme disease symptoms persist. A new review of studies behind current medical advice says those studies prove nothing. Continues →Recent in: Poor Research
Global TV News: Why Lyme disease is on the rise, explained
[CanLyme Note: Both AIDS and Lyme disease arose as an issue in the late 1970’s with the first case of Lyme reported in Quebec in 1977. As pointed out in this piece, since then there have been over 11,000 clinical trials for AIDS yet only 60 for Lyme disease. Lyme disease research funding in Canada is abysmal and is directed Continues →
The new draft of the Infectious Disease Society of America (IDSA) guidelines open for public comment for 45 days.
The IDSA has presented their draft guidelines which with a brief scan appear not much different then their old controversial poorly evidenced guidelines. Much of the same old players and 3 token patients. Typical unequal representation. Public comments close August 10th. Take your time, make notes before you enter their controlled comment format process as you have to submit all Continues →
The Scientist – Opinion: The “Money Culture” in Academic Biomedical Research
[CanLyme Note: This for profit money drive takes medical research away from cure to ‘a drug for every symptom’. In Canada, relative to Lyme disease, the private Association of Medical Microbiology and Infectious Disease of Canada (AMMI), is an extension of the ‘do not cure’ medical money machine. They offer opinion and poorly designed research to support the ‘do not treat Continues →
Lyme advocates say Canada offers “toxic tokenism” to patients
The Canadian government recently announced new investment in Lyme disease research. However, Canadian Lyme advocates fear that the patient voice will be excluded from the decision-making process. In the following article, the Canadian Lyme Consortium (CLC)–made up of advocates, patients, researchers and practitioners–offers background and context. By Vett Lloyd, PhD; Liz Zubek, MD, CCFP FCFP; Sue Faber and Jennifer Kravis, co-founders, LymeHope; Janet Sperling, CanLyme; Linda Kelso, Continues →
Interview: The flawed science behind the current global Lyme policies, diagnostics and treatment
Posted on on-lyme.org Dec 2nd, 2017 Written by Huib Holly Ahern is a professor of microbiology as well as the mother of a child that was severely affected by Lyme Disease. Because of this personal experience and her professional background and training, she was able to dissect the flaws in scientific reasoning that underlie decades of wrong policies, invalid diagnostics and Continues →
Human seroprevalence of Borrelia miyamotoi in Manitoba, Canada, in 2011–2014: a cross-sectional study
[CanLyme Note: This is a very interesting and important study and we are pleased that this is being looked at but there are some glaring omissions in the document. Not made clear in the results is that a significant percentage of obviously symptomatic patients (why their blood was tested in the first place) would be completely missed using the current two Continues →
Anti-science old guard taking last dying breaths of continuing to misinform physicians using tax payer dollars
Here is their opinion article title, amazing in 2017 how poorly they reference their evidence… “False and Misleading Information about Lyme Disease” Here is one of their uniformed statements, “Persistent, unexplained subjective symptoms such as chronic fatigue and pain are common in the general population. Annual surveys by the Centers for Disease Control and Prevention (CDC) indicate that approximately Continues →
Flunk the Lyme test? Just wait and get sicker
January, 2017, Huffington Post Sin Lee, a pathologist and scientist, believes the deck is stacked in the quest to air new ideas on Lyme disease. Too many science journals telling him to take his research elsewhere. Too many deftly worded rejections. Too little inclination to engage in a fair fight over the facts and fiction of Lyme disease. Dr. Lee’s Continues →
CanLyme director responds to Canadian Medical Association Journal article
Response to Doctors Gregson and Quach Robert G. Murray, DDS, Director, CanLyme Re: “The Lyme law” Zubek, 187:520-521doi:10.1503/cmaj.115-0029 The problem with Lyme disease in Canada will only continue to grow to the point where the numbers affected will simply overwhelm the idea that Lyme Borreliosis (LB) is hard to catch and easy to treat with a short round of antibiotics. Continues →
Doctor comments on Lyme disease treatment
[CanLyme note: It is very common for mainstream physicians who subscribe to the Infectious Disease Society of America guidelines to design studies in such a fashion that the outcome is pre-determined. These studies have no value, nor scientific merit. The divide is created intentionally.] Infectious Disease doctor, Sam Donta, responds to article, To the Editor: I am responding to the Continues →
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library
Frontiers in Microbiology, May 23, 2016 Although currently recommended antibiotics for Lyme disease such as doxycycline or amoxicillin cure the majority of the patients, about 10–20% of patients treated for Lyme disease may experience lingering symptoms including fatigue, pain, or joint and muscle aches. Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body Continues →
Watch CTV news interview of Dr. Todd Hatchette. A very good example of how opinion, not science, is driving Lyme borreliosis policy in Canada… in spite of evidence presented by experts in Ottawa, May 15th to 17th, 2016.
[Lyme disease is actually Lyme borreliosis. an infection caused by many different strains/genotypes of Borrelia bacteria] How can one rationalize making progress from the patient’s expert perspective when officially, by tax payer funded microbiologists, opinion is put forward as fact with no supporting science. Dr. Todd Hatchette attended the recent three day conference in Ottawa during which a wide diversity Continues →
New Lyme Disease Study Reveals Strong Reporting Bias
David Michael Conner Huffington Post On March 31, the New England Journal of Medicine published a study that concludes, “In patients with persistent symptoms attributed to Lyme disease, longer-term antibiotic treatment did not have additional beneficial effects on health-related quality of life beyond those with shorter-term treatment.” Read full article
Physicians and patients weigh in on latest poorly designed study that raises the question, “Why?”, and, “Who is driving this spin?”
Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease Comment “Persister research needs to account for morphological variability of Lyme The patient population studied was already a group that had shown persistence of disease. These would be “treatment failures” and more difficult cases. Even in this difficult population every group who received 2 weeks of IV ceftriaxone made Continues →
Chronic Lyme European PLEASE Trial—You know it’s spin when treatment “success” is called “failure”?
March 30th, 2016 Today a widely anticipated clinical trial on chronic Lyme disease from Europe called PLEASE was published in the New England Journal of Medicine (NEJM). The press has given the trial a twenty trumpet salute with a MedPage headline reading “Long-Term Antibiotics Fail Again in Lyme Disease–Focus on Lyme and antibiotics for persistent symptoms called unhelpful.” Here’s the Continues →